Scott Kaatz, Waqas Qureshi, Christopher Fain, David Paje. Duration of Anticoagulation Treatment in Patients With Venous Thromboembolism. J Am Osteopath Assoc 2010;110(11):638–644. doi: 10.7556/jaoa.2010.110.11.638.
Download citation file:
Deep vein thrombosis and pulmonary embolism are clinical manifestations of venous thromboembolism, and they necessitate anticoagulant therapy in most cases. The duration of treatment is predicated on a balance between the risk of recurrent disease and the risk of bleeding inherent to anticoagulant therapy. It is important that physicians are aware of evidence-based guidelines that can enhance decision-making discussions with patients about the risks and benefits of the different durations of treatment. Keeping patients well informed as they consider these difficult choices helps them assume responsibility and may improve compliance in accordance with the tenets of osteopathic principles of care.
Patients with cancer-related VTE are at a substantially higher risk of developing recurrence, and they present a unique set of clinical challenges.
It is unclear whether immobilization, pregnancy, use of female hormones, or history of long distance travel should also be considered as provoking VTE.
This PDF is available to Subscribers Only
View Article Abstract & Purchase Options